证券代码：300347 证券简称：泰格医药 公告编码（2025）029 号 杭州泰格医药科技股份有限公司 2024 年度权益分派实施公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或 者重大遗漏负连带责任。 特别提示： 2、根据《公司法》的规定，上市公司通过回购专用证券账户持有的公司股份不享 有参与利润分配的权利。因此，公司享有利润分配权的股份总额为总股本扣除本公司回 购专用证券账户持有的股份数量。【注：截至本公告日，公司回购专用证券账户持有A股 股份5,883,780股，公司未进行H股股份回购。】 按照分配比例不变的原则，调整后的2024 年度A股权益分派方案如下：以本公告日A股总股本737,901,250股扣减公司回购专户持有 股份5,883,780股后可参与分配的A股总股数732,017,470股为基数，向全体股东每10股派 发现金股利3.000000元（含税），共计派发现金红利219,605,241.00元（含税）。剩余未分 配利润，结转以后年度分配；公司不以资本公积金向全体股东转增股本。 3、按照公司A股总股本（含公司回购专户持有的股份）折算的每股现金分红=实际 ...

数据统计显示，中证医疗指数近一个月上涨4.50%，近三个月下跌4.01%，年至今上涨1.46%。 从中证医疗指数持仓样本的行业来看，医药卫生占比97.55%、信息技术占比2.18%、主要消费占比 0.27%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。特殊情况下将对指数进行临时调整。当样本退市时，将其从指数样 本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处理。 金融界6月6日消息，A股三大指数收盘涨跌不一，中证医疗指数 (中证医疗，399989)下跌0.94%，报 6591.32点，成交额113.31亿元。 据了解，中证医疗指数选取业务涉及医疗器械、医疗服务、医疗信息化等医疗主题的医药卫生行业上市 公司证券作为指数样本，以反映医疗主题上市公司证券的整体表现。该指数以2004年12月31日为基日， 以1000.0点为基点。 从指数持仓来看，中证医疗指数十大权重分别为：药明康德（11.63%）、迈瑞医疗（9.59% ...

Group 1 - The Tianhong Innovation Drug ETF (517380) experienced a decline of 1.68% on June 5, yet it attracted a net inflow of 6.45 million yuan, marking the second consecutive day of net inflows, totaling over 18.2 million yuan [1] - As of the latest close, the fund's shares reached a historical high of 668 million [1] - The ETF recorded a single-day trading volume of 25.09 million yuan, the highest since April 2023 [1] Group 2 - Aijian Securities expressed optimism regarding the trend of Chinese innovative drugs entering global markets, highlighting that the recent ASCO conference showcased significant research achievements [2] - The Chinese pharmaceutical industry is positioned in the global first tier for ADC, bispecific antibodies, and cell therapy, with clear advantages in R&D and production costs [2] - The increasing recognition and influence of Chinese innovative drugs in the global market is expected to accelerate the trend of innovation going abroad, creating a positive feedback loop [2]

Core Insights - The CXO industry appears to have emerged from a downturn in 2025, with notable profit growth among key players such as WuXi AppTec (89.06%), Hangzhou Tigermed Consulting (32.54%), and Kelun Pharmaceutical (15.83%) [2] - However, Tigermed stands out as the only major player in the CXO sector experiencing a decline, with a 29.61% year-on-year drop in Q1 2025 following a 79.99% decline in 2024 [2][3] Financial Performance - In Q1 2025, Tigermed reported revenue of 1.564 billion yuan, a decrease of 5.79% year-on-year, and a net profit of 165 million yuan, down 29.61% [3] - The gross margin fell from 37.83% in Q1 2024 to 30.03% in Q1 2025, indicating significant challenges in profitability [3] - For the full year 2024, Tigermed's revenue was 6.603 billion yuan, a decline of 10.58%, with net profit plummeting to 405 million yuan, a drop of 79.99% [4][7] Profitability Metrics - Tigermed's profitability has sharply declined, with gross margin decreasing from 47.43% in 2020 to 33.95% in 2024, and further to 30.03% in Q1 2025 [5] - The net profit margin also fell from 63.56% in 2020 to 6.78% in 2024, highlighting a severe reduction in profitability [5] Market Dynamics - The decline in Tigermed's performance is attributed to increased competition and a reduction in financing for innovative drug companies, which impacts order volumes [8][9] - In 2024, the domestic innovative drug financing dropped to approximately 4.2 billion USD, a nearly 20% decrease, affecting cash flow for many companies [9] Strategic Positioning - Tigermed operates as both a CRO service provider and an investment entity, which has created challenges during industry downturns [10] - As of the end of 2024, Tigermed held non-current financial assets worth 10.1 billion yuan, including equity investments in several medical companies [10] - The company reported a significant loss of 502 million yuan in fair value changes in 2024, which heavily impacted its net profit [10] Contractual Developments - Despite the challenges, Tigermed secured new contracts worth 10.12 billion yuan in 2024, with a net increase of 8.42 billion yuan after cancellations, indicating some resilience [10] - In Q1 2025, the net new contract amount exceeded 2 billion yuan, reflecting a 20% year-on-year growth, primarily driven by demand from multinational pharmaceutical companies [11] Expansion Efforts - Tigermed has also completed the acquisition of Japanese CRO Medical Edge to accelerate its overseas expansion [12] - The effectiveness of these measures in mitigating the impact of investment volatility remains uncertain [12]

Group 1 - The core viewpoint of the articles highlights that Tigermed's stock closed at 51.61 yuan, down 2.35%, with a rolling PE ratio of 132.44 times, and a total market capitalization of 44.438 billion yuan [1] - The average PE ratio for the medical services industry is 40.82 times, with a median of 45.93 times, placing Tigermed at the 42nd position in the industry ranking [1] - As of the first quarter of 2025, 80 institutions hold shares in Tigermed, including 78 funds, 1 social security fund, and 1 other entity, with a total shareholding of 170.6648 million shares valued at 8.671 billion yuan [1] Group 2 - Tigermed's main business is providing comprehensive clinical trial services as a Contract Research Organization (CRO) for new drug development, offering solutions for global pharmaceutical and medical device innovation companies [1] - The latest financial results for the first quarter of 2025 show that the company achieved operating revenue of 1.564 billion yuan, a year-on-year decrease of 5.79%, and a net profit of 165 million yuan, down 29.61% year-on-year, with a gross profit margin of 30.03% [1] - The PE ratios for Tigermed compared to industry averages indicate a significant premium, with the industry average PE at 40.82 times and Tigermed's PE at 132.44 times, suggesting potential overvaluation [2]

Group 1 - The pharmaceutical sector has recently experienced a significant pullback, with the innovative drug concept seeing a net outflow of nearly 2.5 billion yuan in A-shares [1] - The Tianhong Innovative Drug ETF (517380) reached a new high for the year before experiencing a substantial decline, dropping 2.75% with a trading volume of 22 million yuan, and most constituent stocks fell nearly 5% [1] - The Tianhong Innovative Drug ETF is the only product tracking the Hang Seng-Hu-Shen-Hong Kong Innovative Drug Selected 50 Index, which includes leading innovative drug companies from the three markets [1] Group 2 - Dongwu Securities predicts that 2025 will mark the explosive growth of China's innovative drug industry, driven by three core factors: significant BD transactions, profitability turning points for leading companies, and an improving policy environment [2] - Guosheng Securities acknowledges short-term trading pullback risks but emphasizes the solid underlying logic and clear trends in the innovative drug sector, maintaining a positive outlook for the innovative drug bull market [2] - The market size of China's innovative drugs is expected to exceed 2 trillion yuan by 2030, with a compound annual growth rate of 24.1% [2]

Group 1 - The CSI 300 Index has seen a slight decline of 0.09% as of June 5, 2025, with mixed performance among constituent stocks, highlighting a volatile market environment [1] - The CSI 300 ETF has recorded a trading volume of 202 million yuan, with an average daily trading volume of 1.255 billion yuan over the past year, ranking among the top three comparable funds [1] - The latest scale of the CSI 300 ETF has reached 168.307 billion yuan, indicating significant investor interest and participation [1] Group 2 - Leverage funds are increasingly positioning themselves in the market, with a net financing purchase amount of 8.8768 million yuan on the previous trading day and a total financing balance of 1.088 billion yuan [1] - The valuation of the CSI 300 Index is at a historical low, with a price-to-book (PB) ratio of 1.3, which is below 81.03% of the time since the index's inception, suggesting attractive valuation opportunities [1] - The top ten weighted stocks in the CSI 300 Index account for 23.22% of the index, with notable companies including Kweichow Moutai, CATL, and Ping An Insurance [1] Group 3 - East Wu Securities emphasizes the solid foundation for China's high-quality economic development and the transition between old and new growth drivers, indicating a positive long-term economic outlook [2] - Citic Securities predicts a potential annual-level rally in Chinese equity assets over the next year, with a significant shift in market style from small-cap stocks to core asset trends [2] Group 4 - Investors without stock accounts can access core A-share assets through the CSI 300 ETF linked fund (160724), providing an opportunity for low-cost entry into the market [3]

Group 1 - The core viewpoint of the news highlights the performance and potential of the innovative drug sector, particularly focusing on the Tianhong Innovative Drug ETF (517380), which has seen a year-to-date increase of 25.96% as of June 4, 2023 [1] - The Tianhong Innovative Drug ETF (517380) is the only ETF tracking the Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drug Selected 50 Index, which includes leading innovative drug companies from the three markets [1] - The ETF has experienced a net inflow of 11.76 million yuan recently, indicating strong investor interest and confidence in the innovative drug sector [1] Group 2 - Recent developments in domestic innovative drugs were highlighted, particularly the presentation of self-developed anti-cancer drugs by China Biopharmaceutical at the American Society of Clinical Oncology (ASCO) annual meeting [2] - The "De Fu Combination" treatment showed promising results in clinical trials, outperforming the global leader in cancer treatment, Pembrolizumab, with a median progression-free survival of 11 months [2] - Analysts from Donghai Securities and Guosheng Securities express optimism about the innovative drug sector, emphasizing its solid underlying logic and potential for continued growth despite short-term market concerns [2]

Core Viewpoint - The A-share medical service sector experienced a short-term decline, with significant drops in several companies' stock prices, indicating potential market volatility in this industry [1] Company Summary - Jinkai Biotechnology saw a decline of over 8% in its stock price [1] - Other companies that followed the downward trend include Sunshine Nuohuo, Tigermed, Hongbo Pharmaceutical, Berry Genomics, and Chengdu Xian Dao [1]

Group 1: Company Overview - Wuhan Dazhong Dental Medical Co., Ltd. (Dazhong Dental) and Hansi Aitai Biopharmaceutical Technology (Wuhan) Co., Ltd. (Hansi Aitai) have recently submitted their listing applications to the Hong Kong Stock Exchange (HKEX) for the second time [1] - Dazhong Dental operates 92 institutions, including 4 hospitals and 80 outpatient departments, covering 8 cities in Hubei and Hunan provinces [2] - Dazhong Dental holds a market share of approximately 2.6% in the private dental service sector in Central China, ranking first among its peers [2] Group 2: Business Segments - Dazhong Dental's main business includes three segments: comprehensive dental treatment services, dental implant services, and orthodontic services, with comprehensive dental treatment accounting for over 50% of total revenue [2] - The company has shown strong customer retention, with a revisit rate increasing from 75.3% in 2022 to 79.6% in 2024 [2] Group 3: Financial Performance - Dazhong Dental's revenue for 2022, 2023, and 2024 was 409 million yuan, 442 million yuan, and 407 million yuan, respectively, while net profit attributable to the parent company was 43.3 million yuan, 50.1 million yuan, and 41.9 million yuan [3] - The company attributed the decline in 2024 performance to consumer downgrade and intensified competition in the dental service industry [3] - The average cost of dental implant services dropped over 30% from 8,460 yuan in 2022 to 5,767 yuan in the first half of 2024 due to national procurement policies [3] Group 4: Investment and Capital Operations - Dazhong Dental previously received investments from institutions such as CITIC Securities and others, but these investors chose to exit before the second listing application in September 2024 [3] - The company repurchased 8.3793 million shares from six investors for 121 million yuan [3] Group 5: Hansi Aitai Overview - Hansi Aitai is an innovative biopharmaceutical company focusing on structural biology, translational medicine, and clinical development, with a core product HX009, a dual-function antibody fusion protein [4] - The company has submitted an updated H-share listing application to HKEX after a previous application expired [4] Group 6: Financial Performance of Hansi Aitai - Hansi Aitai reported losses of 84.623 million yuan in 2023 and 117 million yuan in 2024, primarily due to R&D costs and other operational expenses [5] - R&D costs accounted for 73.0% and 61.8% of total operating expenses in 2023 and 2024, respectively [4][5] Group 7: Investment and Future Outlook for Hansi Aitai - Hansi Aitai has attracted investments from notable institutions and completed a B+ round of financing in June 2024, achieving a post-investment valuation of 1.615 billion yuan [5] - The company has indicated that it will continue to face significant net losses in the foreseeable future and may not achieve or maintain profitability [5]